A Phase 1/2 interventional study of BNT162b2 and mRNA-1273 in COVID-19 and Breakthrough Infection, sponsored by Chang Gung Memorial Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-25.
Sponsored by Chang Gung Memorial Hospital · Phase 1/2, Interventional, and Prevention
The severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) specific antibody and neutralizing antibody level induced by adenovirus vector vaccines were lower than mRNA vaccines. Vaccine efficacy of ChAdOx1 nCoV-19 was lower than BNT162b2 and mRNA 1273 in clinical trials. The emergence of highly transmissible and mutant variants of SARS-COV-2 has raised the concern of COVID-19 vaccine effectiveness. The complete vaccination rate is still low in Taiwan. Strict border control measures are imposed by Central Epidemic Command Center. However, the measure of quarantine for flight crew is considered one of the breach of COVID-19 infection control. Despite most of the flight crew has fully vaccinated, several episodes of breakthrough infection occurred among flight crew resulting in domestic infection recently. Low neutralizing antibody was found in a proportion of fully vaccinated flight crew and healthcare workers. A 3rd booster COVID-19 dose is considered for flight crew and healthcare workers. This study is to determine the safety, reactogenicity, and immunogenicity of heterologous 3rd booster of mRNA and protein COVID-19 vaccines.
Safety concerns of COVID-19 ChAdOx1 nCoV-19 vaccine have led to a recommendation of heterologous boost with mRNA vaccine in several countries. Initial safety data of heterologous prime-boost with ChAdOx1 nCoV-19 and BNT162b2 vaccines showed well-tolerated. No major differences in reactogenicity were observed between homologous and heterologous vaccination. Immunogenicity of heterologous ChAdOx1 nCoV-19 and BNT162b2 vaccination is better compared with homologous ChAdOx1 nCoV-19 vaccination. Despite the scarcity of safety and immunogenicity of heterologous ChAdOx1 nCoV-19 and mRNA 1273 vaccination, the preliminary reports revealed similar findings. Although both T and B memory cells contribute to the protection, there is evidence that neutralizing serum antibody levels have high correlates of protection for symptomatic SARS-COV-2 infection. The SARS-COV-2 specific antibody and neutralizing antibody level induced by adenovirus vector vaccines were lower than mRNA vaccines. Vaccine efficacy of ChAdOx1 nCoV-19 was lower than BNT162b2 and mRNA 1273 in clinical trials. In the real world, the ChAdOx1 nCoV-19 vaccine appeared less effective than the BNT162b2 and mRNA1273 vaccine in preventing SARS-COV-2 infection. The emergence of highly transmissible and mutant variants of SARS-COV-2 has raised the concern of COVID-19 vaccine effectiveness. The S protein of the widespread SARS-COV-2 delta variant reduced the binding of neutralizing antibodies. Breakthrough infections are increasing worldwide. Vaccine effectiveness decreased significantly after the emergence of the SARS-COV-2 delta variant. Waning immunity is another potential cause of breakthrough infection. Centers for Disease Control of the United States has advocated 3rd booster dose of mRNA vaccine for people at risk of COVID-19 and those who work in high-risk settings including healthcare workers. Israel expanded its 3rd COVID-19 vaccine boost to those aged over 12 years old. The complete vaccination rate is still low in Taiwan. Strict border control measures are imposed by Central Epidemic Command Center. However, the measure of quarantine for flight crew is considered one of the breaches of COVID-19 infection control. Despite most of the flight crew has fully vaccinated, several episodes of breakthrough infection occurred among flight crew resulting in domestic infection recently. Low neutralizing antibody was found in a proportion of fully vaccinated flight crew and healthcare workers. A 3rd booster COVID-19 dose is considered for flight crew and healthcare workers. This study is to determine the safety, reactogenicity, and immunogenicity of heterologous 3rd booster of mRNA and protein COVID-19 vaccines.
With waning vaccine induced immunity and emergence of potent immune evasion SARS-CoV-2 omicron variant, previous virus and vaccine-induced immunity have failed to prevent transmission. Build-up of herd immunity through vaccination is no longer achievable so far. On the other hand, SARS- CoV-2 omicron induced immunity has been shown low cross-protective against other variants. Omicron breakthrough infection can boost existing immunity induced by vaccination. The neutralizing titer elicited by omicron breakthrough infection are much higher than that induced by 3 doses of mRNA vaccines. Hybrid immunity by vaccination and omicron breakthrough infection can elicit effective cross-neutralizing antibodies against most variants.
More than 10% of population in Taiwan have infected with omicron variant. Second booster vaccination is being advocated for health care workers. The study of dynamics of immunogenicity induced by third dose heterologous booster vaccination needs to be revised. Immunogenicity including SARS-CoV-2 anti- spike IgG, the 50% neutralizing antibody titer and IFN-secreting T cells specific to whole spike protein will be performed at 180 days after booster vaccination as schedule. Additional memory T cell epitopes and memory B cell epitopes will be studied. Some participants have been infected with the omicron variant. We will compare differences of memory T cell epitopes and memory B cell epitopes between uninfected participants and omicron breakthrough infected participants. Besides, second booster vaccination is planning to be administered in health care workers. We will compare differences of memory T cell epitopes and memory B cell epitopes between 2 boosters vaccinated participants and SARS-CoV-2 breakthrough infected participants. Immunogenicity study will be conducted 28 days after the second booster vaccination and 28 days after SARS-CoV-2 breakthrough infection. Immunogenicity study, including SARS-CoV-2 anti- spike IgG, the 50% neutralizing antibody titer (NT50) and IFN-secreting T cells specific to whole spike protein, will be compared between participants with 2 booster vaccination and SARS-CoV-2 breakthrough infection.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 340 is above the median of 100 across 4,099 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Chang Gung Memorial Hospital is the lead sponsor of 1,064 studies on the registry; 235 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The participant may not enter the trial if ANY of the following apply:
The participants in this group will receive BNT162b2 30ug as the booster dose.
Biological: BNT162b2
The participants in this group will receive mRNA-1273 50ug as the booster dose.
Biological: mRNA-1273
The participants in this group will receive mRNA-1273 100ug as the booster dose.
Biological: mRNA-1273
The participants in this group will receive MCV COVID-19 vaccine 15ug as the booster dose.
Biological: MVC-COV1901
BNT162b2 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
mRNA-1273 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
MCV COVID-19 vaccine is a protein subunit vaccine containing S2P S-protein which passes the EUA by Taiwan FDA.
The immune response after heterologous boost third dose of COVID-19 vaccines after homologous prime-boost AZD1222 vaccination
Immunogenicity studies include SARS-CoV-2 anti-spike IgG, the 50% neutralizing antibody titer (NT50) and IFN - secreting T cells specific to whole spike protein.
Time frame: Day 28 after third dose boost
The immune response after heterologous boost third dose of COVID-19 vaccines after homologous prime-boost AZD1222 vaccination
Immunogenicity studies include SARS-CoV-2 anti-spike IgG, the 50% neutralizing antibody titer (NT50), IFN - secreting T cells specific to whole spike protein, and Memory T cell epitopes and memory B cell epitopes by flow cytometry.
Time frame: Day 180 after third dose boost
The immune response after heterologous boost fourth dose of COVID-19 vaccines after homologous prime-boost AZD1222 vaccination
Immunogenicity studies include SARS-CoV-2 anti-spike IgG, the 50% neutralizing antibody titer (NT50), IFN - secreting T cells specific to whole spike protein, and Memory T cell epitopes and memory B cell epitopes by flow cytometry.
Time frame: Day 28 after second booster vaccination.
The immune response of breakthrough infection after heterologous boost third dose of COVID-19 vaccines after homologous prime-boost AZD1222 vaccination
Immunogenicity studies include SARS-CoV-2 anti-spike IgG, the 50% neutralizing antibody titer (NT50), IFN - secreting T cells specific to whole spike protein, and Memory T cell epitopes and memory B cell epitopes by flow cytometry.
Time frame: Day 28 after breakthrough infection (after receiving third doses of any COVID-19 vaccine)
The safety of heterologous boost third dose of COVID-19 vaccines
Evaluation of the safety profile included Solicited local adverse events (AEs), solicited systemic AEs, AE of special interest (AESI), and serious adverse events (SAEs)
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
Plan to share: No
This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chang Gung Memorial Hospital